Hi, what are you looking for?
By Colin Kellaher
Nektar Therapeutics on Thursday said it would regain full rights to rezpegaldesleukin from partner Eli Lilly & Co., which is ending a licensing agreement following the failure of the compound in a Phase 2 study in systemic lupus erythematosus.
San Francisco-based Nektar said it plans to work quickly to initiate a Phase 2b…
Read the full article here
Genesco Inc. (NYSE:GCO) Q3 2025 Earnings Conference Call December 6, 2024 8:30 AM ET Company Participants Darryl MacQuarrie – Senior Director of FP&AMimi Vaughn...
Listen below or on the go on Apple Podcasts and Spotify Handling market volatility with long-term dividend growth investing. Prioritizing future dividends over immediate...
This article was written by Follow Cash Builder Opportunities (aka Nick Ackerman) is a former fiduciary and a registered financial advisor with 14 years...
This article was written by Follow True Orion is comprised of two notions. Orion, the ancient mythical hunter, and truth. The neverending pursuit for...
